Management of cholestatic disease in 2017. (Q38774857)

6 September 2017

Management of cholestatic disease in 2017. (English)

1 reference

6 September 2017

Elsemieke de Vries

1

1 reference

PubMed ID

28052628

6 September 2017

Ulrich Beuers

series ordinal

2

1 reference

6 September 2017

1 January 2017

1 reference

6 September 2017

1 reference

6 September 2017

37 Suppl 1

1 reference

6 September 2017

123-129

1 reference

Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’

6 September 2017

1 reference

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

Interpreting serological tests in diagnosing autoimmune liver diseases

21 January 2018

1 reference

Mechanisms of tissue injury in autoimmune liver diseases

21 January 2018

1 reference

The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies

21 January 2018

1 reference

A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes.

21 January 2018

1 reference

Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis.

21 January 2018

1 reference

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

21 January 2018

1 reference

Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis

21 January 2018

1 reference

Genetic epidemiology of primary sclerosing cholangitis

21 January 2018

1 reference

Pathogenesis of primary sclerosing cholangitis.

21 January 2018

1 reference

Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.

21 January 2018

1 reference

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis

21 January 2018

1 reference

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

21 January 2018

1 reference

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

21 January 2018

1 reference

Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid

21 January 2018

1 reference

Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice.

21 January 2018

1 reference

Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor

21 January 2018

1 reference

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.

21 January 2018

1 reference

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

21 January 2018

1 reference

Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis

21 January 2018

1 reference

New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond

21 January 2018

1 reference

Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.

21 January 2018

1 reference

Effect of side chain length on biotransformation, hepatic transport, and choleretic properties of chenodeoxycholyl homologues in the rodent: studies with dinorchenodeoxycholic acid, norchenodeoxycholic acid, and chenodeoxycholic acid

21 January 2018

1 reference

Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.

21 January 2018

1 reference

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice

21 January 2018

1 reference

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

21 January 2018

1 reference

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice

21 January 2018

1 reference

Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.

21 January 2018

1 reference

A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements

21 January 2018

1 reference

Identification of a nuclear receptor that is activated by farnesol metabolites

21 January 2018

1 reference

Vitamin D receptor as an intestinal bile acid sensor

21 January 2018

1 reference

Identification of a nuclear receptor for bile acids

21 January 2018

1 reference

Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.

21 January 2018

1 reference

Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents

21 January 2018

1 reference

The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism

21 January 2018

1 reference

A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis

21 January 2018

1 reference

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

21 January 2018

1 reference

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

21 January 2018

1 reference

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

21 January 2018

1 reference

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

21 January 2018

1 reference

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

21 January 2018

1 reference

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

21 January 2018

1 reference

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

21 January 2018

1 reference

Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate.

21 January 2018

1 reference

21 January 2018

Fibrates and cholestasis

1 reference

Fibrate treatment for primary biliary cirrhosis

21 January 2018

1 reference

Bezafibrate for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

21 January 2018

1 reference

No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis

21 January 2018

1 reference

Effects of long-term rifampicin administration in primary biliary cirrhosis

21 January 2018

1 reference

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis

21 January 2018

1 reference

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.13306

1 reference

release_3rq57rsox5ekdnhf4ybqeyecii

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3rq57rsox5ekdnhf4ybqeyecii

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

28052628

1 reference

PubMed ID

28052628